Skip to content
Open access

The use of divozilimab in real-world clinical practice: a prospective, single-centre study

Aug 2026 · Neurology, neuropsychiatry, Psychosomatics · Vol 18, pp. 64-70 · 0 citations · 7 references

TL;DR

DIV therapy, administered at the Regional Centre for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System at Novosibirsk State Regional Clinical Hospital, has confirmed the high efficacy and safety demonstrated in clinical trials.

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, the pathogenesis of which is underpinned by a combination of autoinflammatory and neurodegenerative processes. Divozilimab (DIV) is the first monoclonal antibody from the anti-CD20 therapy group to be developed and authorised in the Russian Federation for the treatment of relapsing-remitting multiple sclerosis (RRMS) and secondary-progressive multiple sclerosis (SPMS) with relapses in patients aged 18 years and over. The relatively recent introduction of DIV into clinical practice means that there is a limited amount of published data from real-world clinical practice. Objective: to investigate the efficacy and safety of DIV in real-world clinical practice at a single medical centre. Material and methods. Forty patients with MS (13 with SPMS) living in the Novosibirsk Region received two doses of DIV (data as at 30 May 2026). Patient data were analysed: clinical [gender, age, clinical manifestations at onset and during relapses, score on the Expanded Disability Status Scale (EDSS), use of disease-modifying therapies, comorbidities, infection status], radiological data (new lesions, enlarged lesions, lesions with contrast enhancement) and laboratory data (complete blood count, urinalysis, blood biochemistry). Efficacy parameters were assessed [mean annual relapse rate (MARR), EDSS score, proportion of patients with confirmed disability progression over 6 months (CDP-6), and radiological activity] as well as safety parameters (number of adverse events, including infectious and oncological events). Results. During DIV therapy, there was a reduction in MARR – from 1.0±0.85 to zero – and in the proportion of patients with radiological activity – from 60% to zero (p<0.05). However, no changes were observed in EDSS scores or in the incidence of CDP-6 (p>0.05). No increase in the number of infectious or oncological events was observed during DIV therapy (p > 0.05). Conclusion. DIV therapy, administered at the Regional Centre for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System at Novosibirsk State Regional Clinical Hospital, has confirmed the high efficacy and safety demonstrated in clinical trials.

Read PDF

Similar papers

Open access Sep 2026

Post-registration experience with divosilimab in patients with secondary progressive multiple sclerosis with recurrence

Introduction . Therapy aimed at eliminating CD20-positive B cells is considered one of the most significant advances in the treatment of multiple sclerosis. Divozilimab is a humanized anti-CD20 monoclonal antibody lacking fucose in its Fc fragment, which enhances its effector properties. Aim . Тo analyze the e...

A. A. Sokolova, L. S. Zemlyanushin, L. Anishchenko et al. · 0 citations
Open access Sep 2026

Late-onset versus adult-onset multiple sclerosis: A comparative analysis of clinical, radiological, and confirmed disability progression.

Patients with LOMS tend to have a higher prevalence of PPMS, a greater burden of comorbidities, higher baseline disability, lower relapse activity, and a shorter time to CDP.

A. Fouad, Abdallah Saad, Hadeer Mohamed Abd El-Aziz et al. · 0 citations
Open access Sep 2026

Telitacicept for primary angiitis of the central nervous system: A real-world retrospective study

Background Primary central nervous system vasculitis (PACNS) is a rare inflammatory disease with limited treatment options. Telitacicept and high-resolution vessel wall imaging (HR-VWI) may offer new strategies for therapy and disease monitoring. Objective To evaluate the clinical efficacy and safety of telitacicept in...

J. Lyu, Yi-Fan Wang, Fang-Fang Li et al. · 0 citations
Open access Sep 2026

Multicenter study of cladribine in relapsing-remitting multiple sclerosis in patients over 50 years.

OBJECTIVE Cladribine is an oral immunomodulatory drug approved for the treatment of relapsing-remitting multiple sclerosis. However, evidence regarding its use in patients over 50 years is limited. The aim of the study was to evaluate the effectiveness and safety of cladribine in patients with relapsing-remitting multi...

M. S. Fortes-González, L. Herrero-Poch, A. Pato-Pato et al. · 0 citations
Open access Sep 2026

Early Recognition of Patients with Neuronopathic Forms of Mucopolysaccharidosis Type II in Clinical Practice

Background: Mucopolysaccharidosis type II (MPS II) is a progressive, rare, X-linked inherited disease with multi-organ involvement and a restricted life expectancy. The disease has two main forms: neuronopathic (severe) and non-neuronopathic (attenuated). Aim: To compare the two main forms of MPS II to identify signs f...

Nataliya V. Buchinskaia, E. Zakharova, Anastasia O. Vechkasova et al. · 0 citations
Open access Sep 2026

29 | INNOVATIVE THERAPEUTIC STRATEGIES IN GENODERMATOSIS: AN ITALIAN MULTICENTRE STUDY

Background. Genodermatoses are a group of rare inherited disorders affecting the skin and its adnexa. Their clinical presentation is heterogeneous, reflecting the wide underlying genetic heterogeneity. The manifestations have a strong impact on the quality of life and on the duration. To date, there are no therapeutic...

Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.